公开(公告)号：US10273237B2

公开(公告)日：2019-04-30

申请号：US15102991

申请日：2014-12-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Chunjian Liu ,  James Lin ,  Ryan M. Moslin ,  David S. Weinstein ,  John S. Tokarski

IPC: C07D487/04 ,  C07D487/14 ,  C07D498/14

Abstract: Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

公开(公告)号：US20160304524A1

公开(公告)日：2016-10-20

申请号：US15102991

申请日：2014-12-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Chunjian Liu ,  James Lin ,  Ryan M. Moslin ,  David S. Weinstein ,  John S. Tokarski

IPC: C07D487/04 ,  C07D498/14

CPC classification number: C07D487/04 ,  C07D487/14 ,  C07D498/14

Abstract: Compounds having the following formula (I), or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

公开(公告)号：US20230167092A1

公开(公告)日：2023-06-01

申请号：US17997288

申请日：2021-04-27

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Chunjian Liu ,  James Lin ,  David S. Weinstein

IPC: C07D403/12 ,  C07D473/00 ,  C07D401/12 ,  C07D405/14 ,  C07D403/14 ,  C07D401/14 ,  C07D487/04 ,  C07D413/14

CPC classification number: C07D403/12 ,  C07D473/00 ,  C07D401/12 ,  C07D405/14 ,  C07D403/14 ,  C07D401/14 ,  C07D487/04 ,  C07D413/14 ,  C07B2200/05

Abstract: There are disclosed compounds of the following formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating inflammatory and autoimmune diseases or disorders.